E-nitiateBio key facts
- Developer of new drugs designed for autoimmune diseases.
- It has raised $42.6M; the latest was Early Stage VC ($27.9M) in Sep 2025.
- Notable investors include Highlight Capital, Fuzhe Capital, HFI Investment Group, Taikun Fund, Hangzhou Linzhuo Industry Investment — 11 tracked in total.
- Status: Privately Held (backing).
Who backs E-nitiateBio
11+- ·The complete investor list: 11 names
- ·Watch E-nitiateBio: the Monday email on marks, rounds and moves
E-nitiateBio funding rounds
No funding rounds for E-nitiateBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
E-nitiateBio investors
11 investors are on record for E-nitiateBio, including Highlight Capital, Fuzhe Capital, HFI Investment Group and Taikun Fund.
About E-nitiateBio
Developer of new drugs designed for autoimmune diseases. The company focuses on researching and developing innovative medicines for dermatology and autoimmune diseases, improving the quality of human life and solving the unmet needs of patients.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- enitiatebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
E-nitiateBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.